|
Real-time Estimate
Cboe Europe
02:20:49 11/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 1,924.50 GBX | +1.05% |
|
+5.23% | +5.40% |
| 09/11 | London's FTSE 100 climbs over 1% as firmer gold prices boost miners | RE |
| 09/11 | Four Weeks of Declines on Wall Street. What Next? |  |
| Market Cap | 76.35B 102B 91.42B 84.13B 145B 9,600B 148B 1,006B 401B 5,140B 384B 376B 16,188B | P/E 2026 * |
15.4x | P/E 2027 * | 12.3x |
|---|---|---|---|---|---|
| Enterprise Value | 98.24B 132B 118B 108B 186B 12,353B 191B 1,295B 516B 6,613B 495B 484B 20,829B | EV / Sales 2026 * |
2.9x | EV / Sales 2027 * | 2.71x |
| Free-Float |
94.95% | Yield 2026 * |
3.65% | Yield 2027 * | 3.93% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
OTC Markets
| GLAXF | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Bulgaria S.E.
| GS71 | End-of-day quote |
Last Transcript: GSK plc
| 1 day | +0.91% | ||
| 1 week | +5.88% | ||
| Current month | +4.31% | ||
| 1 month | +9.26% | ||
| 3 months | +0.39% | ||
| 6 months | +4.91% | ||
| Current year | +6.06% |
| 1 week | 1,802 |  | 1,944.5 |
| 1 month | 1,740 | | 2,158 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,690 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/10/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 13/10/26 | Buy | Executive/Senior Manager | 352 | 0.0000% | ||
| 13/10/26 | Buy | Compliance Officer | 326 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.05% | +5.88% | +9.20% | +38.37% | 102B | |
| +0.34% | +0.54% | +46.59% | +137.07% | 1,258B | |
| -0.58% | +5.85% | +49.53% | +91.33% | 679B | |
| -0.32% | +2.26% | +33.72% | +111.02% | 518B | |
| +0.02% | +2.69% | +43.96% | +69.59% | 390B | |
| -1.25% | +1.94% | +69.99% | +45.45% | 367B | |
| +0.56% | +2.13% | +31.41% | +60.15% | 307B | |
| -0.75% | +1.67% | +6.58% | +38.65% | 293B | |
| -0.75% | +0.59% | +43.35% | +73.57% | 252B | |
| -0.63% | +0.79% | +42.87% | +122.33% | 210B | |
| Average | -0.21% | +1.53% | +37.72% | +78.75% | 438B | |
| Weighted average by Cap. | -0.12% | +1.29% | +42.27% | +94.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.84B 45.39B 40.52B 37.28B 64.13B 4,255B 65.72B 446B 178B 2,278B 170B 167B 7,175B | 35.27B 47.32B 42.24B 38.87B 66.85B 4,435B 68.51B 465B 185B 2,375B 178B 174B 7,479B |
| Net income | 4.92B 6.6B 5.89B 5.42B 9.32B 618B 9.55B 64.82B 25.84B 331B 24.76B 24.23B 1,043B | 6.11B 8.2B 7.32B 6.73B 11.58B 768B 11.87B 80.52B 32.09B 411B 30.76B 30.1B 1,295B |
| Net Debt | 21.89B 29.37B 26.21B 24.12B 41.49B 2,753B 42.52B 289B 115B 1,474B 110B 108B 4,641B | 19.18B 25.73B 22.96B 21.13B 36.34B 2,411B 37.25B 253B 101B 1,291B 96.56B 94.49B 4,066B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/11/26 | GBX 1,924.50 | +1.05% | 1,270,698 |
| 09/11/26 | GBX 1,904.50 | +0.77% | 4,197,242 |
| 06/11/26 | GBX 1,890.00 | 0.00% | 6,698,924 |
| 05/11/26 | GBX 1,890.00 | 0.00% | 5,325,114 |
| 04/11/26 | GBX 1,890.00 | +3.42% | 10,739,102 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
